Why has NICE said this?
NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept were recommended because the benefits to patients justify their cost.